dc.contributor.author | AYDOGAN, Gülcan | |
dc.contributor.author | AKCAY, A | |
dc.contributor.author | ERBEY, F | |
dc.contributor.author | SALCIOGLU, Z | |
dc.contributor.author | AKICI, F | |
dc.contributor.author | OZTURK, G | |
dc.contributor.author | Tugcu, Deniz | |
dc.date.accessioned | 2021-03-03T11:34:58Z | |
dc.date.available | 2021-03-03T11:34:58Z | |
dc.identifier.citation | AKCAY A., Tugcu D., AYDOGAN G., ERBEY F., SALCIOGLU Z., AKICI F., OZTURK G., "Best treatment option for infantile chronic myeloid leukemia patients: imatinib or hematopoietic stem cell transplantation?", Pediatric transplantation, cilt.18, ss.316-7, 2014 | |
dc.identifier.issn | 1397-3142 | |
dc.identifier.other | av_28bdd98d-5e75-4ad2-a392-c82490942c38 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/32236 | |
dc.identifier.uri | https://doi.org/10.1111/petr.12234 | |
dc.language.iso | eng | |
dc.title | Best treatment option for infantile chronic myeloid leukemia patients: imatinib or hematopoietic stem cell transplantation? | |
dc.type | Makale | |
dc.relation.journal | Pediatric transplantation | |
dc.contributor.department | , , | |
dc.identifier.volume | 18 | |
dc.identifier.startpage | 316 | |
dc.identifier.endpage | 7 | |
dc.contributor.firstauthorID | 180820 | |